New hope for rare, painful skin disease: experimental drug EPN-701 enters phase 2 trial
NCT ID NCT07583745
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests a new drug called EPN-701 for calciphylaxis, a rare condition causing painful skin sores with no approved treatment. About 60 adults with moderate to severe pain and at least one open sore will receive the drug. The main goals are to see if EPN-701 safely reduces pain and shrinks the sores over 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CALCIPHYLAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renal Associates
Boston, Massachusetts, 02114, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an arthritis drug stop a deadly skin condition?
- Rare, deadly skin condition under the microscope: french study sheds light on calciphylaxis
- New study aims to crack the code of deadly skin hardening in kidney patients
- Amniotic stem cells tested for rare, painful skin condition in kidney patients
- Oxygen chamber therapy put to the test for dozens of diseases